(Q39812986)

14 September 2017

title

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion (English)

1 reference

14 September 2017

0 references

11

Steven G Reed

1 reference

14 September 2017

10

Rhea N Coler

1 reference

14 September 2017

Susan L Baldwin

1

1 reference

14 September 2017

Narek Shaverdian

2

1 reference

14 September 2017

Yasuyuki Goto

3

1 reference

14 September 2017

Malcolm S Duthie

4

1 reference

14 September 2017

Vanitha S Raman

5

1 reference

14 September 2017

Tara Evers

6

1 reference

14 September 2017

Farah Mompoint

7

1 reference

14 September 2017

Thomas S Vedvick

8

1 reference

14 September 2017

Sylvie Bertholet

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

11 August 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

27

1 reference

14 September 2017

issue

43

1 reference

14 September 2017

page(s)

5956-5963

1 reference

New vaccine approaches for seasonal and pandemic influenza.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Antibody response to influenza vaccination in the elderly: a quantitative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Immune response to influenza vaccination in a large healthy elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Serum IgG subclass antibody responses in children vaccinated with influenza virus antigens by live attenuated or inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Role of the B-cell response in recovery of mice from primary influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Diminished influenza A virus-specific MHC class I-restricted cytotoxic T lymphocyte activity among elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

TLR4 agonists as immunomodulatory agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Taking toll: lipid A mimetics as adjuvants and immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Plasma cells for a lifetime?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Molecular and cellular signatures of human vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Scientific barriers to developing vaccines against avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Cell-mediated protection in influenza infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

Bone marrow is a major site of long-term antibody production after acute viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.081

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.07.081

1 reference

14 September 2017

1 reference